Saudi Arabia’s M&A volume hits $955m in Q1, fueled by chemicals sector

Saudi Arabia was the only country in the region to show activity in the chemical sector in the first quarter of 2024. Shutterstock
Short Url
Updated 21 June 2024
Follow

Saudi Arabia’s M&A volume hits $955m in Q1, fueled by chemicals sector

RIYADH: Saudi Arabia led the Middle East in mergers and acquisitions in the chemicals sector in the first quarter of 2024, with $500 million worth of deals, according to recent data.

Figures from financial markets platform Dealogic showed that the Kingdom’s total M&A deal volume during this period reached $955 million, with the chemicals sector accounting for 52.4 percent of the total. 

Saudi Arabia was the only country in the region to show activity in this sector, and a report from management consulting firm Kearney earlier this month suggested that chemical executives are expecting more M&As led by strategic investors such as national oil companies.

“Recent deals by major players like Aramco and ADNOC underscore the region’s commitment to leveraging M&A as a key growth lever, setting the stage for a dynamic and transformative period ahead,” said Jose Alberich, partner, Middle East and Africa at Kearney at the time.

The figures from Dealogic revealed that the professional services sector was the second targeted sector, with deals worth $160 million, accounting for a 16.8 percent share of the Kingdom’s total.

Technology was close behind with $138 million in deal value, capturing a 14.5 percent share. 

Retail and insurance sectors represented 7 percent and 4.1 percent of the total, respectively.

Across the region

The figures revealed that during the first three months of the year, the Middle East targeted M&A volume reached $6.21 billion, with technology being the leading sector with 42 total deals worth $1.56 billion. 

Finance followed with 9 deals amounting to $1.3 billion, while the oil and gas sector, which topped the list a year ago with deals valued at $3.5 billion, fell to the eighth place with just $273 million in deals.

According to Dealogic, domestic transactions were the dominant contributor, making up 55 percent of the Middle East’s M&A volume across 91 deals. In contrast, outbound transactions accounted for 45 percent with a total of 38 deals.

Kuwait emerged as the top contributor to GCC nations’ total M&A deal volume, amounting to $1.12 billion, all of which were outbound deals.

The UAE followed closely with a deal value of $988 million, of which 58 percent were domestic.

Saudi Arabia secured the third position with 18 deals valued at $955 million, of which 60 percent were outbound.

Compared to the same quarter of 2023, the Middle East’s deal volume declined by 27 percent. 

Global slowdown

In its report, Dealogic explained that global M&A activity experienced a significant decline during this period, with the number of transactions falling by 31 percent to 7,162, marking one of the quietest quarters for dealmakers in nearly two decades.

The slowdown was largely attributed to high capital costs, with Switzerland being the only major economy to cut interest rates in 2024. 

Additionally, geopolitical tensions, including the emergence of the Middle East as a new trouble hotspot alongside ongoing conflicts involving Russia and Ukraine, and tensions between Washington and Beijing over Taiwan, further contributed to the subdued activity in deal making.

Drivers of activity

In a paper published in September, the Boston Consulting Group said government support has been a driving force behind significant M&A activities among emerging market players in recent years, particularly in the Middle East, as firms aim at expanding their global presence.

Saudi Arabia’s SABIC acquired a 31.5 percent stake in Clariant, nearing the 33.3 percent threshold for a mandatory takeover bid under Swiss law. 

The UAE’s state-owned ADNOC purchased a 24 percent interest in OMV, increasing its indirect stakes in Borealis and Borouge, and is in talks to merge them.

ADNOC also made an $11 billion offer for Covestro, which was rejected, and expressed interest in Brazil’s Braskem. These moves highlight a trend of leveraging government support to enhance regional footprints and integrate into global value chains

Additionally, Saudi Aramco acquired Valvoline Inc.’s global products business for $2.7 billion in 2023. This acquisition, according to BCG, enhances Aramco’s lubricant portfolio by integrating Valvoline’s manufacturing and distribution network and its research and development capabilities.

The research highlighted three additional key reasons driving changes in macro trends in M&A, portfolio diversification, vertical integration, and technology acquisition.

Companies are increasingly expanding their portfolios through acquisitions to enter new markets and product segments, often over extended periods. Additionally, the focus has shifted from traditional feedstock-focused acquisitions to sustainable diversification of petrochemical value chains, prioritizing higher-margin and less cyclical businesses.

In essence, this means that rather than primarily acquiring companies to secure raw materials, the emphasis is now on achieving sustainable and balanced growth across the petrochemical value chain. The current priority is to invest in businesses that generate higher profits and are less affected by market fluctuations. This shift aims to create a more resilient and profitable business model in the long term.

This strategic emphasis on specialties is fostering vertical integration into downstream segments, as evidenced by significant acquisitions by industry leaders such as Saudi Aramco, SABIC, Thailand’s PTT, and Malaysia’s PETRONAS.

According to the BCG paper, gaining or retaining technology leadership is a key driver for M&A activity. Acquisitions and joint ventures are crucial for positioning companies as major suppliers in the e-mobility segment and the related electronic chemicals and battery industry.

As demand for sustainable solutions grows, companies are increasingly recognizing the potential of e-mobility. Through strategic M&A, including technology acquisitions and research and development investments, they aim to secure competitive advantages in this rapidly expanding market.

According to Dealogic, technology-focused deals accounted for 21 percent of the global M&A activity in the first three months of 2024. This was followed by healthcare at 14 percent and finance at 11 percent. 

Oil and gas stood at 9 percent, with utility and energy at 7 percent, and real estate and property sectors representing 5 percent of the total M&A activity.

AI attracting funds

Dealogic’s report highlighted that the largest global technology deals were driven by artificial intelligence. The surge in AI has significantly boosted Nvidia’s market capitalization to $2.4 trillion, with the company making investments in seven AI-related firms during this period.

Saudi Arabia also plans to establish a $40 billion fund dedicated to investing in artificial intelligence, according to a report from the New York Times in March. 

Set to launch in the second half of 2024 and spearheaded by Saudi Arabia’s Public Investment Fund, it aims to attract partnerships with US venture capital firm Andreessen Horowitz and other financiers, according to the report.

It will focus on supporting various AI-related ventures in Saudi Arabia, including chip makers and large-scale data centers, NYT wrote at the time.


AI’s shift toward proactive healthcare

Updated 05 February 2026
Follow

AI’s shift toward proactive healthcare

  • Experts reveal how AI is reducing burnout and streamlining workflows

JEDDAH: Artificial intelligence is increasingly moving from the margins of healthcare innovation into its operational core. Rather than replacing clinicians, AI is being deployed to address persistent challenges across health systems, from administrative overload and staff burnout to fragmented data and inefficient patient flow.

Speaking to Arab News, Abbes Seqqat, chief executive officer of Rain Stella Technologies, and Eric Turkington, chief product officer, discussed how AI is already transforming healthcare delivery — and why its impact is most meaningful when embedded directly into clinical workflows rather than treated as a standalone tool.

Seqqat describes AI’s role as accelerating a structural shift in healthcare delivery. “AI is accelerating the shift in healthcare from reactive to proactive care, because AI fundamentally helps detect, analyze and predict,” he said, noting that many health systems lack the resources to perform these tasks at scale.

Abbes Seqqat, chief executive officer of Rain Stella Technologies. (RST photo)

While AI use cases in healthcare are broad, Seqqat emphasized that the most effective applications today focus on operational and clinical fundamentals, including reducing administrative burden, identifying patient risks earlier, and capturing clinical data more reliably and in real time.

RST’s portfolio reflects this approach, spanning surgical data capture and workflow automation, cloud-based electronic medical records, and health information exchange. Across these systems, the common goal is improving data quality and usability so clinicians can spend less time managing information and more time delivering care.

According to Turkington, RST’s systems rely on a mix of established and emerging AI technologies.

RST's Equinox offers a streamlined workflow, minimizing redundant data entry, and also allows for seamless integration with other systems. (RST images)

“Across the portfolio, we are using a wide range of AI and predictive technologies, from voice technology to reliably capture clinician inputs, to large language models that analyze and act on collected data,” he said.

A key focus has been adapting AI to regional and clinical realities. Voice models, for example, have been trained on UAE and GCC accents and grounded in medical terminology to improve accuracy in real-world settings. RST also uses retrieval-augmented generation and multi-agent AI architectures, allowing different AI components to perform specialized tasks such as classifying surgical notes, identifying unusual events, or assisting with billing and coding, Turkington explained.

DID YOU KNOW?

• AI can detect, analyze, and predict patient risks faster than traditional methods.

• Systems like Equinox use voice input and predictive analytics to actively support clinical decisions.

• AI assistants provide real-time updates, automate documentation, and improve coordination in operating theaters.

One of the central concerns around AI adoption is whether it adds complexity to already demanding clinical roles. Seqqat argues the opposite should be the goal.
“For nurses and frontline staff, AI’s greatest contribution is removing the invisible administrative friction that leads to burnout,” Seqqat said.

In operating theaters, AI systems can replace manual coordination methods such as phone calls and whiteboards by providing real-time situational awareness. By automating updates, anticipating delays, and serving as an on-demand clinical notepad, AI reduces cognitive load and allows staff to remain focused on patient care, he explained.

RST’s voice-enabled assistant, Orva, is designed specifically for perioperative environments.

Orva captures live updates through voice input, enabling it to surface delays, flag bottlenecks, and prompt coordination between departments. (RST photo)

Turkington said it enables hands-free documentation and coordination, helping surgical teams manage schedules and resources more effectively.

By capturing live updates through voice input, Orva can surface delays, flag bottlenecks, and prompt coordination between departments. It also assists with documentation and coding, reducing errors and supporting more accurate reimbursement— an area where incomplete records often create downstream challenges.

Electronic medical records remain central to healthcare delivery, but Turkington noted that AI can move them beyond passive data repositories.

Eric Turkington, chief product officer of Rain Stella Technologies. (RST photo)

“We designed Equinox as an EMR that enables you to spend less time with the software and more time with patients,” Turkington said.

Through voice input, automated documentation from visual annotations, and AI-generated pre-visit summaries, the system can actively support clinicians rather than slow them down. Predictive analytics, such as identifying no-show risks or highlighting care gaps, further shift EMRs toward decision-support tools rather than administrative obligations.

Both executives stressed that AI’s effectiveness depends heavily on data access and quality. Seqqat pointed to interoperability as a prerequisite rather than an afterthought.
“AI is only as powerful as the data it can access,” he said, adding that fragmented records limit both clinical insight and system-wide learning.

Health information exchanges, such as RST’s Constellation platform, enable patient data to be viewed longitudinally across providers. AI can then assist with patient identity matching and population-level analysis, allowing trends and risks to be identified across large datasets.

Turkington shared an example from an operating theatre where AI helped prevent cascading delays. When a surgical case ran late, a nurse verbally updated Orva that the patient was ready to exit. The system alerted the recovery unit, analyzed schedule conflicts, and prompted management to reassign staff before delays affected subsequent procedures.

Opinion

This section contains relevant reference points, placed in (Opinion field)

By tagging the cause of the delay and feeding that data into predictive models, the system helped prevent similar issues in the future — without additional manual coordination.

According to Seqqat, the primary returns from AI adoption come from combining efficiency with financial accuracy. Streamlined workflows allow providers to treat more patients without compromising care, while improved documentation reduces revenue leakage.

Looking ahead, Seqqat sees AI becoming central to Saudi Arabia’s healthcare transformation. He described its role as advancing smart hospitals, predictive patient flow, and precision medicine aligned with Vision 2030 goals.
“The role of AI in Saudi Arabia’s healthcare sector is evolving from a supporting technology to a foundational pillar of the Kingdom’s Vision 2030 transformation. Over the next few years, we expect to see AI move into the realm of smart hospitals, where predictive analytics optimize patient flow and AI-driven precision medicine leverages the Saudi Genome Program to provide hyper-personalized care. By unifying national health data and automating complex administrative workflows, AI will enable a more proactive, value-based healthcare model that improves patient outcomes and operational efficiency across the country.”